Načítá se...
Evidence for Effective Multiple K(+)-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V(2) Receptor
Tolvaptan (TLV), an oral non-peptide antagonist of vasopressin V(2) receptor, has been increasingly used for managements in patients with hyponatremia and/or syndrome of inappropriate antidiuretic hormone secretion. However, none of the studies have thus far been investigated with regard to its poss...
Uloženo v:
| Vydáno v: | Front Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6401633/ https://ncbi.nlm.nih.gov/pubmed/30873020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00076 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|